AMRI, a global contract research and manufacturing organization, has appointed Ian Shott as president of AMRI Europe.
In the newly created role, Shott will be responsible for AMRI's business operations in Europe, including the company's site in Wales, U.K., and work closely with AMRI's European-based business development team. As the founder of Excelsyn, acquired by AMRI in 2010, and with more than 20 years experience working with global pharmaceutical, biotechnology and chemical companies, Shott is well-fit to lead AMRI's sales growth in European markets, as well as the worldwide effort to continue to expand revenue growth at the Wales manufacturing location.
Shott also serves as managing director of Shott Consulting, where he provides consulting services to the health care and chemical industries, as well as leading industry boards for the British government in science, technology, innovation and business development.
Perviously, he has held executive board posts at RhodiaChirex in France, Chirex in the U.S., Lonza in Switzerland, and Astra Zeneca in the U.K. He has been particularly involved in creating and/or transforming businesses by a combination of break out development, culture change, organic growth, internal re-engineering and external merger, acquisition and divestment.